Clinical trial and pharmacokinetic phase II 30-minute infusion of PM02734 [Irvalec] every three weeks in patients with metastatic non-small cell lung(NSCLC) previously treated squamous cell with at least one line of platinum-based chemotherapy. [Ensayo clinico y farmacocinetico de fase II de infusion de 30 minutos de PM02734 (Irvalec) cada tres semanas en pacientes con cancer no microcitico de pulmon (CNMP) epidermoide previamente tratado con al menos una linea de quimioterapia con platino]

Trial Profile

Clinical trial and pharmacokinetic phase II 30-minute infusion of PM02734 [Irvalec] every three weeks in patients with metastatic non-small cell lung(NSCLC) previously treated squamous cell with at least one line of platinum-based chemotherapy. [Ensayo clinico y farmacocinetico de fase II de infusion de 30 minutos de PM02734 (Irvalec) cada tres semanas en pacientes con cancer no microcitico de pulmon (CNMP) epidermoide previamente tratado con al menos una linea de quimioterapia con platino]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2012

At a glance

  • Drugs Elisidepsin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2012 Status changed from recruiting to discontinued.
    • 02 Apr 2012 Planned End Date changed to 18 Nov 2010.
    • 18 Dec 2008 Recruitment is expected to last 12 months, as reported by PharmaMar.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top